CytomX Therapeutics (CTMX) PT Lowered to $8 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Price: $2.23 --0%
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 3
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 3
Join SI Premium – FREE
BTIG analyst Kaveri Pohlman lowered the price target on CytomX Therapeutics (NASDAQ: CTMX) to $8.00 (from $16.00) while maintaining a Buy rating.
You May Also Be Interested In
- CytomX Therapeutics to Present at Upcoming November Investor Conferences
- Ibotta Inc (IBTA) PT Raised to $58 at Evercore ISI
- Ambit Capital Upgrades GE Vernova T&D India (GVTD:IN) to Buy (1)
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
